Items tagged with Diagnostics
Drug shortages threaten US anti-TB efforts (post with simple image)
Mounting problems with accessing life-saving products to diagnose and treat TB threaten the progress made against this communicable disease.
Reduced treatment delays for people with drug-resistant TB and HIV co-infection through decentralised care and rapid Xpert MTB/RIF test (post with simple image)
Decentralisation of drug-resistant tuberculosis (DR-TB) management and use of the Xpert MTB/RIF test improves the time from clinic presentation to treatment from 50 days to 7 days in a population with a high burden of HIV and TB co-infection, according to a study from Khayelitsha, South Africa, presented at the 20th International AIDS Conference (AIDS 2014) on Monday.
New tuberculosis blood test in children is reliable and highly specific (post with simple image)
A newly developed test (TAM-TB assay) is the first reliable immunodiagnostic assay to detect active tuberculosis in children.
UNITAID: Tuberculosis diagnostics technology and market landscape – 3rd edition (post with simple image)
The report highlights current and emerging technologies from over 80 manufacturers and developers, including products which are smaller, simpler and easier to use in decentralized settings than the current tools used by the majority of high-burden TB countries.
Meeting report: High-priority target product profiles for new tuberculosis diagnostics (post with simple image)
Report of a consensus meeting convened by the Global TB Programme of the World Health Organization.
UNITAID’s EXPAND-TB and TBXpert MTB-RIF projects detect over a quarter of all MDR-TB cases (post with simple image)
Geneva, 22nd October 2014 – UNITAID welcomes new data in the World Health Organization’s new global report on tuberculosis (TB) which shows a 30% increase in case detection of multi-drug resistant TB (MDR-TB) in 2013, much of which is attributed to the roll out of the UNITAID-funded EXPAND-TB and TBXpert projects.
Cepheid, FIND & Rutgers announce collaboration for next-generation innovations to game-changing Xpert MTB/RIF test (post with simple image)
Xpert MTB/RIF Ultra, the next-generation test for Mycobacterium tuberculosis, will be with increased sensitivity to aid in detection of patients with smear-negative TB, which is often associated with HIV co-infection.
New WHO publication: Xpert MTB/RIF implementation manual (post with simple image)
Technical and operational ‘how-to’: practical considerations
The Union's SPARK-TB Plus program introduces Xpert MTB/RIF testing to the private sector in Uganda (post with simple image)
20 January 2015 - Uganda - The introduction and WHO endorsement of the Xpert MTB/RIF assay in 2010 revolutionized TB diagnosis. The assay's improved sensitivity and specificity compared with smear microscopy means it is able to confirm TB disease in smear negative patients. This provides a huge benefit to people living with HIV/AIDS who often test negative by smear microscopy. In addition, the Xpert MTB/RIF test reduces the time needed to diagnose resistance to rifampicin from six weeks to just two hours. In Uganda, the first GeneXpert system was placed in the National Referral Hospital in Mulago in 2011. Since then, the National TB and Leprosy Program (NTLP) has installed 59 systems countrywide.
Case study of Xpert MTB/Rif implementation in Brazil (post with simple image)
This case study documents the experience of a pilot study to implement Xpert®MTB/Rif to replace sputum smear microscopy to diagnose pulmonary tuberculosis in Brazil's Unified Health System in two municipalities.
Page 29 of 33 · Total posts: 0←First 28 29 30 Last→